Does MGUS Weaken Your Immune System?

MGUS does weaken the immune system, though often in subtle ways that don’t produce obvious symptoms for years. A large population-based study from Sweden found that people with MGUS had roughly double the risk of developing infections compared to matched controls, a gap that persisted across both five- and ten-year follow-up periods. The immune disruption involves multiple arms of the defense system, from antibody production to the bacteria-eating cells of the innate immune response, and the extent of the damage varies considerably from person to person.

The Infection Risk Is Real and Broad

The clearest evidence that MGUS compromises immunity comes from infection data. In a study of more than 5,300 MGUS patients and over 20,000 matched controls drawn from Swedish population records, MGUS was associated with a statistically significant increased risk of both bacterial and viral infections. The bacterial infections that showed up more often included pneumonia, blood infections, kidney infections, cellulitis, bone infections, endocarditis, and meningitis. On the viral side, influenza and shingles were both significantly more common in the MGUS group.¹

That breadth matters. This isn’t a vulnerability to one narrow category of pathogen. MGUS patients were more susceptible to germs that healthy immune systems handle through different mechanisms: bacteria that require antibodies and phagocytes, viruses that depend on T-cell responses, and reactivating viruses like the one behind shingles that require ongoing immune surveillance. The pattern suggests that MGUS touches multiple parts of the immune machinery, not just one.

How MGUS Suppresses Normal Antibody Production

The most well-documented immune problem in MGUS is something called immunoparesis: the abnormal clone of plasma cells crowds out or suppresses the production of the other types of antibodies your body needs. Your immune system makes several classes of antibodies (IgG, IgA, IgM), and in MGUS, the levels of the classes not being produced by the abnormal clone often drop below normal.

The degree of this suppression varies. In a study of nearly 1,000 MGUS patients at the Mayo Clinic, about 27% showed suppression of their uninvolved antibody types when measured with sensitive testing. That’s a meaningful minority, though it also means the majority of MGUS patients had relatively preserved antibody production at diagnosis.²

For those who do have immunoparesis, the consequences go beyond infection risk. A study in JAMA Oncology found that patients with two suppressed uninvolved antibody types had dramatically higher odds of eventually progressing to multiple myeloma compared to those with no immunoparesis. The progression rate in the most suppressed group was roughly 29%, compared to about 3% in those with normal antibody levels.³ So immunoparesis is both a marker of immune weakness and a warning sign of possible disease progression.

Vaccine Responses Tell a Mixed Story

If MGUS weakens your immune system, you might expect vaccines to work less well. The reality is more nuanced than a simple yes or no, and it depends on the vaccine and the individual patient’s disease burden.

For pneumococcal vaccination, the news is reassuring. A study of MGUS patients receiving the 13-valent pneumococcal conjugate vaccine found that 95% of them mounted a positive antibody response, compared to 100% of healthy controls. The difference was not statistically significant.⁴

Influenza vaccination, however, paints a different picture. Research has shown that MGUS patients with higher levels of the abnormal M-protein had depressed influenza-specific antibody responses and failed to boost those antibodies after vaccination.⁵ Further investigation revealed that high M-protein was associated with a restricted memory B-cell response, and up to half of MGUS patients showed signs of limited antibody diversity in at least one antibody class. That restricted repertoire appears to undermine the long-term immune memory that vaccines depend on.⁶

The practical takeaway: vaccines are still worth getting if you have MGUS. Most patients respond to them. But if your M-protein level is on the higher end, the protection you get from certain vaccines may be less robust, and your doctor may want to check antibody levels after vaccination in some cases.

Neutrophils Don’t Work as Well Either

The immune changes in MGUS go beyond antibodies. Neutrophils are the front-line cells that engulf and destroy bacteria, and research has found they are already impaired in MGUS, well before any progression to myeloma. In laboratory testing, neutrophils from MGUS patients showed significantly reduced ability to engulf bacteria compared to neutrophils from healthy donors. The phagocytic activity in MGUS neutrophils was comparable to that seen in myeloma patients and dramatically lower than in healthy controls. The oxidative burst, the chemical weapon neutrophils use to kill swallowed bacteria, was also reduced.⁷

This finding is striking because neutrophils are your most abundant white blood cells and your first responders against bacterial infection. If they’re sluggish in MGUS, it helps explain why the infection risk extends to so many types of bacteria, from skin infections to bloodstream infections to pneumonia. The neutrophil dysfunction appears to be driven by chronic activation signals in the bone marrow environment, essentially leaving these cells in a state where they’ve already been partially “used up” before encountering an actual threat.

T Cells and Natural Killer Cells

The adaptive immune system’s other major branch, the T-cell arm, also shows changes in MGUS. Research has documented increased levels of regulatory T cells and signs of T-cell exhaustion even in MGUS patients who are far from developing myeloma.⁸ Regulatory T cells are immune cells that dial down immune responses. They normally prevent autoimmune disease, but having too many of them can suppress the immune system’s ability to fight infections and tumors. T-cell exhaustion refers to T cells that have been chronically stimulated to the point where they no longer respond effectively.

Natural killer cells, which patrol for virus-infected and cancerous cells, appear to hold up better in MGUS. Studies suggest that NK cells remain functional in MGUS patients, though they may begin to lose their killing ability as disease progresses toward full-blown myeloma.⁹ That’s a small piece of good news: at least one branch of the innate immune system seems to hold the line during the MGUS stage.

The picture with myeloid-derived suppressor cells, another immune-regulating cell type that researchers have worried about in blood cancers, also seems relatively stable. A study comparing bone marrow and blood samples found no significant differences in these suppressor cell populations between healthy donors and MGUS patients.¹⁰

The M-Protein Level Matters a Lot

Not everyone with MGUS faces the same degree of immune compromise. One of the strongest predictors of infection risk is the concentration of the abnormal M-protein. In the Swedish population study, patients whose M-protein was above 2.5 g/dL at diagnosis faced the highest infection risks.¹ The same pattern showed up in the influenza vaccine studies, where higher M-protein correlated with weaker antibody responses and more restricted B-cell diversity.

There’s an important caveat, though. The Swedish data also showed that even patients with very low M-protein levels, below 0.5 g/dL, had a statistically increased infection risk compared to controls.¹ So while higher M-protein means more immune disruption, even a small amount of abnormal protein production signals that something in the immune system has gone awry. The dose-response relationship is real but imperfect; MGUS doesn’t require a large protein burden to start affecting immune function.

The Inflammation Connection

MGUS doesn’t just suppress immune defenses. It also appears to stoke chronic inflammation. A genetic analysis using Mendelian randomization identified causal links between two inflammatory signaling molecules, CXCL10 and IL-6, and the risk of developing MGUS. Genetically higher IL-6 levels were associated with roughly three-and-a-half-fold higher odds of MGUS.¹¹ This suggests that chronic inflammation may both contribute to the development of MGUS and be amplified by it, creating a feedback loop.

Abnormal cytokine secretion is also thought to drive the progression from MGUS to myeloma. Research comparing the molecular landscapes of MGUS and myeloma has identified aberrant cytokine signaling as a central feature of disease evolution, leading to immune dysfunction and activation of growth-promoting pathways in the abnormal plasma cells.¹² For the patient, this means that the inflammatory environment created by MGUS is not just a side effect. It’s part of the biology that determines whether the condition stays stable or advances.

When the Abnormal Antibody Attacks Your Own Tissue

In some cases, the monoclonal antibody produced in MGUS doesn’t just sit in the blood harmlessly. It can target the body’s own tissues, most commonly the myelin coating of peripheral nerves. IgM-type MGUS, in particular, is associated with immune-mediated neuropathies. In one documented pattern, the abnormal IgM antibody targets a protein called myelin-associated glycoprotein (MAG), leading to a slowly progressive demyelinating neuropathy that causes numbness, tingling, weakness, and sometimes balance problems.¹³

This is worth knowing about because it changes the meaning of “undetermined significance.” For someone whose MGUS is causing nerve damage, the condition has very determined clinical significance, even though the underlying plasma cell population is small and not cancerous. If you develop progressive numbness or weakness in your hands or feet and have MGUS, the two are worth connecting for your doctor.

Can Infections Actually Push MGUS Toward Myeloma?

A worrying question that researchers have been circling is whether the infections that MGUS makes you vulnerable to might themselves accelerate the progression toward myeloma. There’s intriguing evidence on both sides of this relationship. Studies from the iStopMM screening program in Iceland have noted that inflammatory and infectious diseases may be associated with triggering progression of plasma cell malignancies, suggesting that the predisposition to infections could feed back into disease biology.¹⁴

Separately, research examining the actual targets of the monoclonal antibody in MGUS and myeloma patients has found that in a subset of cases, the abnormal antibody recognizes proteins from common infectious agents, including Epstein-Barr virus. Myeloma patients whose abnormal antibody targeted an Epstein-Barr virus protein had greater bone marrow infiltration and higher levels of inflammation-linked cytokines compared to other myeloma patients.¹⁵ The implication is provocative: for some people, the original immune response to a common infection may be what went wrong in the first place, and repeated stimulation of that misguided immune response could fuel disease progression.

This remains an area of active investigation rather than settled science. But it reinforces the importance of taking infection prevention seriously if you have MGUS, not only for the immediate health risk but potentially for long-term disease stability.

Why Aging Makes Everything Harder

MGUS is overwhelmingly a condition of older adults. The average age at diagnosis is in the late sixties or early seventies, which means the immune changes from MGUS are layered on top of the normal age-related decline in immune function. The natural aging of the immune system involves many of the same problems seen in MGUS: reduced antibody diversity, more exhausted T cells, slower innate immune responses, and higher baseline inflammation. A review in Frontiers in Immunology noted that this age-related immune decline compounds the deficits from MGUS, with immune function deteriorating incrementally as the disease progresses toward its symptomatic phase.¹⁶

For patients, this means the immune impact of MGUS cannot be cleanly separated from the immune impact of being older. A 75-year-old with MGUS who catches pneumonia may be dealing with the combined effects of an aging immune system, reduced normal antibodies, sluggish neutrophils, and chronic inflammation from the abnormal clone. Teasing apart how much each factor contributed is nearly impossible in practice, but the additive nature of these deficits is what makes the infection risk clinically meaningful.

Effects on Bone and the Marrow Environment

The immune disruption in MGUS extends to the bone marrow environment itself. MGUS patients have elevated markers of bone turnover, with increased activity of osteoclasts (the cells that break down bone). Specifically, levels of a signaling molecule called RANKL, which drives osteoclast formation, are elevated in MGUS compared to healthy controls. However, unlike in myeloma, the bone formation side of the equation appears to still compensate for this increased breakdown, which is why MGUS patients don’t typically develop the bone lesions seen in myeloma.¹⁷

This matters for the immune system because the bone marrow is where most immune cells are born and mature. The signaling molecules involved in bone turnover, including RANKL and various cytokines, also influence how immune cells develop. An abnormal marrow environment doesn’t just affect bones; it shapes the quality and quantity of immune cells that emerge from it.

Early Gut Microbiome Changes

A newer area of research is exploring whether the gut microbiome shifts along the spectrum from MGUS to myeloma. Preliminary profiling of fecal samples from MGUS, smoldering myeloma, and active myeloma patients found that bacterial composition changed across the disease stages. MGUS patients had relatively higher levels of certain bacterial groups, while myeloma patients showed increased total bacterial abundance along with overgrowth of different genera. Researchers speculated that loss of immune surveillance by myeloid and lymphoid cells could explain the shifting bacterial populations as disease progresses.¹⁸

This is still very early-stage research with small sample sizes, and it’s not yet clear whether gut changes in MGUS are a cause, a consequence, or merely a bystander of the immune disruption. But given the increasingly recognized role of gut bacteria in immune regulation, it’s a thread worth watching.

Can Exercise or Lifestyle Changes Help?

Given that MGUS has no approved treatment (the standard approach is monitoring, often called “watchful waiting”), patients understandably want to know whether anything they can do on their own might shore up their immune function. A pilot study tested whether a short-term progressive exercise program could improve immune markers in MGUS and smoldering myeloma patients. The results were sobering: the exercise program produced no measurable changes in T-cell populations, no shifts in markers of T-cell exhaustion, and no changes in senescence markers.¹⁹

That doesn’t mean exercise is useless for people with MGUS. Physical activity has well-established general health benefits, including cardiovascular fitness, mood improvement, and overall quality of life, all of which matter when living with a chronic condition. But the specific immune dysfunction driven by the abnormal plasma cell clone appears to be resistant to lifestyle interventions, at least based on what has been studied so far. The immune changes are rooted in the biology of the disease itself, in the abnormal cells and the microenvironment they create in the marrow, rather than in something that aerobic fitness or diet can easily override. For now, the most practical immune-protective strategies for MGUS patients remain staying current on vaccinations, seeking prompt treatment for infections, and maintaining regular follow-up with a hematologist to catch any signs of progression early.